✦ LIBER ✦

Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study

✍ Scribed by M. Nowicki; I. Rychlik; H. Haller; M. Warren; L. Suchower; I. Gause-Nilsson; K-M. Schützer

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of the dipeptidyl pe

✍ I. Raz; M. Hanefeld; L. Xu; C. Caria; D. Williams-Herman; H. Khatami; Sitaglipti 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 160 KB

Long-term safety, tolerability, and effi

✍ Masato Odawara; Takashi Kadowaki; Naoko Tajima; Mikio Nishii; Tadaaki Taniguchi; 📂 Article 📅 2011 🏛 Springer Japan 🌐 English ⚖ 377 KB

Efficacy and safety of the dipeptidyl pe

✍ R. E. Pratley; M. S. Kipnes; P. R. Fleck; C. Wilson; Q. Mekki; Alogliptin Study 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 157 KB

Efficacy and safety of the dipeptidyl pe

✍ K. Hermansen; M. Kipnes; E. Luo; D. Fanurik; H. Khatami; P. Stein; Sitagliptin S 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 175 KB

Saxagliptin is non-inferior to glipizide

✍ B. Göke; B. Gallwitz; J. Eriksson; Å. Hellqvist; I. Gause-Nilsson; for the D1680 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 274 KB

Efficacy and safety of adding the dipept

✍ M. A. Nauck; G. C. Ellis; P. R. Fleck; C. A. Wilson; Q. Mekki; for the Aloglipti 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 218 KB